


The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement, for which the directors (the “Directors”) of Sino Biopharmaceutical Limited (the “Company”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”) for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading; there are no other matters the omission of which would make any statement in this announcement misleading; and all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

CLARIFICATION ANNOUNCEMENT

The Board refers to certain newspaper articles which report plans of the Company to list its Shares on the Main Board, to set up a new factory in Hainan Island, the PRC, to acquire certain domestic pharmaceutical companies in the PRC, to place Shares with certain investors, and to spin-off Jiangsu Chiatai-Tianqing.

The Directors would like to emphasize that the Board may or may not proceed with any of the above plans.

If there is any further information on any of the above plans that is required to be disclosed under the GEM Listing Rules or that the Board has decided to implement any of the above plans, the Board will comply with the relevant requirements under the GEM Listing Rules.

The board of Directors (the “Board”) refers to certain newspaper articles on 27 April, 2002 in Apple Daily and Hong Kong Commercial Daily which report plans of the Company to list its Shares on the main board (the “Main Board”) of the Stock Exchange, to set up a new factory in Hainan Island, the People’s Republic of China (the “PRC”), to acquire certain domestic pharmaceutical companies in the PRC, to place Shares with certain investors, and to spin-off Jiangsu Chiatai-Tianqing Pharmaceutical Co., Ltd. (“Jiangsu Chiatai-Tianqing”), a 60 per cent. owned subsidiary of the Company.

The Directors would like to clarify that the Board has been briefed by certain advisers, on a preliminary basis, the feasibility of listing of the Shares on the Main Board. The Board has not made any decision or commitment in respect of such proposal.

The Board is also studying a proposed investment in a new factory in Hainan Island, the PRC to be made by Shandong Chia Tai Freda Pharmaceutical Co., Ltd. (“Chia Tai Freda”), a 55 per cent. owned subsidiary of the Company, in an estimated aggregate amount of RMB12 million. Chia Tai Freda is in the preliminary process of completing the required legal formalities which is expected to be done by the first half of the year 2003. The Company and its subsidiaries (together, the “Group”) have not signed any contractual document relating to this proposed investment, and the Directors expect that the internal resources of the Group will finance this investment if it is made by the Group. This investment will not constitute a notifiable transaction (as defined in the GEM Listing Rules) for the Company.

With regard to the proposed acquisition of certain domestic pharmaceutical production companies in the PRC, the Directors confirm that they are in preliminary discussions with certain parties for business co-operations, but would like to emphasize that such discussions may not result in any acquisition transaction to be entered into by the Group.

The Board is in preliminary discussion on the possibility of spinning off Jiangsu Chiatai-Tianqing, but has not made any decision as to particulars and timing of the proposed spin-off.

The Directors would like to emphasize that the Board may or may not proceed with any of the above plans.

If there is any further information on any of the above plans that is required to be disclosed under the GEM Listing Rules or that the Board has decided to implement any of the above plans, the Board will comply with the relevant requirements under the GEM Listing Rules.

By order of the Board
Sino Biopharmaceutical Limited
Tse Ping
Chairman

Hong Kong, 30 April, 2002

This announcement will remain on the GEM website with the domain name of www.hkgem.com on the “Latest Company Announcements” page for at least seven days from the day of its posting.